Status:
UNKNOWN
Assessment of Change in Atherosclerotic Plaque by Serial CCTA
Lead Sponsor:
Yonsei University
Collaborating Sponsors:
Chong Kun Dang Pharmaceutical Corp.
Conditions:
Coronary Artery Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Eligibility:
All Genders
19+ years
Brief Summary
Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, a...
Eligibility Criteria
Inclusion
- Patients who underwent clinically indicated CCTA (index CCTA)
- Mild to moderate stenosis (25-69%) on CCTA
- ≥1 clinical risk factors (Smoking, HTN, HDL\<40, Premature FHx, M ≥45, F ≥55) for CAD
Exclusion
- Acute coronary syndrome (unstable angina or MI)
- Positive (not equivocal) stress test
- Contraindications to statin
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2020
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03414840
Start Date
April 1 2018
End Date
October 31 2020
Last Update
June 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea, 120-752